tiprankstipranks
Trending News
More News >
Tsubota Laboratory Incorporated (JP:4890)
:4890
Japanese Market
Advertisement

Tsubota Laboratory Incorporated (4890) AI Stock Analysis

Compare
1 Followers

Top Page

JP:4890

Tsubota Laboratory Incorporated

(4890)

Select Model
Select Model
Select Model
Neutral 62 (OpenAI - 4o)
Rating:62Neutral
Price Target:
¥363.00
▲(6.76% Upside)
The overall stock score is primarily influenced by strong financial performance, particularly in revenue growth and operational efficiency. However, technical indicators suggest bearish market sentiment, and the high P/E ratio indicates potential overvaluation. The lack of earnings call data and corporate events limits additional insights.

Tsubota Laboratory Incorporated (4890) vs. iShares MSCI Japan ETF (EWJ)

Tsubota Laboratory Incorporated Business Overview & Revenue Model

Company DescriptionTsubota Laboratory Incorporated engages in the research and development of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, and presbyopia. The company was incorporated in 2012 and is based in Tokyo, Japan.
How the Company Makes MoneyTsubota Laboratory generates revenue through multiple streams, primarily from the sale of its optical products, including prescription lenses and eyewear. The company has established partnerships with healthcare providers, optical retailers, and distributors, which facilitate the distribution of its products to a broader audience. Additionally, Tsubota Laboratory invests in research and development to create new technologies and products, which can lead to increased sales. The company may also earn revenue from licensing its proprietary technologies and engaging in collaborations with other firms in the optical and healthcare industries, further diversifying its income sources.

Tsubota Laboratory Incorporated Financial Statement Overview

Summary
Tsubota Laboratory Incorporated shows strong revenue growth and operational efficiency, reflected in improved profit margins. The balance sheet is solid, with low leverage and a strong equity base. However, cash flow challenges need to be addressed to ensure long-term sustainability and growth potential.
Income Statement
75
Positive
The company demonstrated strong revenue growth, with a significant increase from 2024 to 2025. Gross profit margins are high, indicating efficient production and cost management. However, the net profit margin has been volatile, with a significant loss in 2024 followed by a recovery in 2025. The EBIT and EBITDA margins have improved, reflecting better operational efficiency.
Balance Sheet
80
Positive
The balance sheet is robust, with a strong equity position and a low debt-to-equity ratio, indicating financial stability. The company has a high equity ratio, suggesting a solid capital structure. However, the decrease in cash and short-term investments over the years warrants attention.
Cash Flow
60
Neutral
The cash flow statement shows challenges, with negative operating cash flow in recent years, indicating potential liquidity issues. Free cash flow has been negative, which could impact future investments and growth. However, the company had positive free cash flow in earlier years, suggesting potential for recovery.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.36B1.36B673.53M954.69M640.92M687.50M
Gross Profit1.16B1.18B21.38M719.14M557.02M606.76M
EBITDA253.28M310.89M-602.60M184.19M241.07M271.61M
Net Income177.43M205.77M-641.32M90.18M153.32M201.61M
Balance Sheet
Total Assets2.02B2.50B2.30B2.67B1.62B1.08B
Cash, Cash Equivalents and Short-Term Investments1.47B1.54B1.88B2.16B1.17B610.77M
Total Debt85.26M90.38M116.90M139.34M223.82M242.35M
Total Liabilities627.88M915.85M927.93M722.59M873.44M487.55M
Stockholders Equity1.39B1.59B1.37B1.95B744.35M591.03M
Cash Flow
Free Cash Flow0.00-331.75M-313.35M-20.27M582.69M-8.63M
Operating Cash Flow0.00-317.75M-301.35M28.49M654.91M36.72M
Investing Cash Flow0.00-14.55M-12.00M-54.03M-72.23M-43.60M
Financing Cash Flow0.00-12.25M35.74M1.01B-18.53M236.97M

Tsubota Laboratory Incorporated Technical Analysis

Technical Analysis Sentiment
Negative
Last Price340.00
Price Trends
50DMA
353.82
Negative
100DMA
370.10
Negative
200DMA
384.51
Negative
Market Momentum
MACD
-3.28
Negative
RSI
45.34
Neutral
STOCH
45.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4890, the sentiment is Negative. The current price of 340 is below the 20-day moving average (MA) of 342.90, below the 50-day MA of 353.82, and below the 200-day MA of 384.51, indicating a bearish trend. The MACD of -3.28 indicates Negative momentum. The RSI at 45.34 is Neutral, neither overbought nor oversold. The STOCH value of 45.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4890.

Tsubota Laboratory Incorporated Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
¥19.36B6.761.85%3.70%37.00%
¥14.46B11.972.40%5.93%-36.11%
¥11.21B15.391.23%4.08%51.63%
¥8.74B48.59101.17%
¥6.16B2.61%15.66%56.93%
¥19.49B3.70%15.00%-195.87%
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4890
Tsubota Laboratory Incorporated
336.00
-107.00
-24.15%
JP:2796
Pharmarise Holdings Corp.
531.00
-76.25
-12.56%
JP:3417
Ohki Health Care Holdings, Inc.
1,401.00
582.31
71.13%
JP:3544
SATUDORA HOLDINGS CO., LTD.
811.00
25.65
3.27%
JP:4350
Medical System Network Co., Ltd.
501.00
92.38
22.61%
JP:8095
Astena Holdings Co.,Ltd.
486.00
-10.85
-2.18%

Tsubota Laboratory Incorporated Corporate Events

Tsubota Laboratory Reports First Quarter Losses Amidst Sales Decline
Aug 7, 2025

Tsubota Laboratory Incorporated reported a decrease in net sales and continuing losses for the first quarter of the fiscal year ending March 31, 2026. Despite a slight improvement in the equity to total assets ratio, the company faces challenges in achieving profitability, with forecasts indicating a modest increase in net sales but a decrease in profits for the full fiscal year.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 25, 2025